細胞内陽性アロステル調節器によるβ2AR調節のメカニズム
Xiangyu Liu1, Ali Masoudi2, Alem W Kahsai2
1Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
まとめ
研究者らは,陽性アロステル調節器に結合したGタンパク質結合受容体の構造を明らかにした. これは,アロステリック薬が治療上の利益のために受容体の形状を安定させる方法を示しています.
科学分野:
- 薬理学について
- 構造生物学
- 生物化学
背景:
- Gタンパク質結合受容体 (GPCR) は重要な薬物標的であり,ほとんどの治療法はオーステリック部位に作用する.
- GPCRのアロステリック部位はあまり理解されず,治療的には未充分に利用されている.
- アロステリック調節を理解することは,新しい治療法の開発の鍵です.
研究 の 目的:
- オーソステルアゴニストと陽性アロステル変調剤 (化合物-6FA) と複合したβ2アドレナリン受容体 (β2AR) の結晶構造を決定する.
- 化合物-6FAの結合部位と作用機構を明らかにする.
- β2ARに対するβ1ARに対する化合物-6FAの選択性を説明する.
主な方法:
- X線結晶学
- オーステリックアゴニストと化合物-6FAによるβ2ARの共結晶化
- 構造分析と比較
主要な成果:
- 結晶構造はβ2ARの内面にあるアロステリック部位に化合物-6FAの結合を明らかにした.
- このアロステリック部位は,細胞内ループ2とトランスメブランセグメント3と4によって形成されます.
- 化合物-6FAは,Gタンパク質の結合に不可欠な細胞内ループ2のα-螺旋形状を安定させる.
- 構造的差異は,β2ARに対するβ1ARに対する観察された選択性を説明する.
結論:
- この研究はβ2ARの陽性アロステリック調節のための構造的基礎を提供します.
- アロステルリンガンドは特定の受容体構造を安定させ,新しい治療戦略を提供することができる.
- アロステルリガンドの多様性は,GPCRの薬剤発見の分野を拡大する可能性を示唆している.
関連する概念動画
Allosteric Regulation
63.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.1K
Positive Regulator Molecules
134.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
134.7K
Positive Regulator Molecules
6.6K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.6K
Cooperative Allosteric Transitions
8.6K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.6K
Cooperative Allosteric Transitions
2.6K
2.6K
Regulated Protein Degradation
8.8K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.8K


